European Psychiatry - Volume 33 - March 2016

712 / 812

S708 24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805
Disclosure of interest The author has not supplied his/her decla-
ration of competing interest.
EV1124
Does clinical change always means the
same? Comparison of different
perspectives
S. Egger ∗ Weniger , S. Prinz , S. Vetter , M. Müller
University Hospital for Psychiatry Zurich, ZIP, Rheinau, Zurich,
Switzerland
∗ Corresponding author.
Introduction In psychiatric practice, the assessment of change
frompre- to post-treatment is a key approach for monitoring treat-
ment effects and for the prediction of treatment outcomes. The
Health of the Nation Outcome Scales (HoNOS) as a clinician-rated
measure and the Brief Symptom Inventory (BSI) as a self-report
measure are tools (that are) often incorporated in outcome mon-
itoring. Their usefulness, however, has been questioned by two
important issues: their psychometric properties and their lack of
concordance.
Aims and objectives The aimof the study is to evaluate the respon-
siveness of HoNOS and BSI as well as their interactions to predict
clinical meaningful change according to the Global Clinical Impres-
sion (CGI) as quasi-gold standard for treatment outcome.
Methods A consecutive sample of patients admitted to a Swiss
psychiatric hospital for either alcohol use disorders, schizophrenic
psychoses, mood disorders, anxiety and somatoform disorders, or
personality disorders was assessed with Brief Symptom Inventory
(BSI) at admission anddischarge. TheHoNOS and the CGI were rated
by the responsible clinicians at admission and discharge. Ordinal
logistic regressions will be conducted using the CGI categories as
ordered categorical outcome. HoNOS and BSI scores as well as their
interaction terms will be used as independent variables.
Results and conclusion Complete data of admission and discharge
is available fromapproximately 600 cases. Graphical presentations
will illustrate the resulting associations.
Keywords Clinical Global Impression; Health of the Nation
Outcome Scales; Brief Symptom Inventory; Outcome monitoring;
Ordinal regression
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1125
Descriptive study of the treatment of
delusional disorder. Survey study
DELIRANDA
B. Girela Serrano ∗, L. Aguado Bailón , P. Calvo Rivera ,
J.E. Mu˜noz Negro , J. Cervilla Ballesteros
1 Hospital Santa Ana Motril, Psiquiatría, Motril, Granada, Spain
2 Hospital Universitario San Cecilio Granada, Psiquiatría, Granada,
Spain
∗ Corresponding author.
Introduction We currently lack clinical guidelines for the treat-
ment of Delusional Disorder (DD) F-22, the low prevalence of the
disease coupled with no awareness of illness and poor adherence
to prescribed treatment make it difficult to study. The limited evi-
dence available for the treatment is based mainly on clinical series.
Objectives This study evaluates the knowledge and preferences
in the treatment of the DD, in order to improve clinical practice and
gain information of the DD to conduct clinical studies of effective-
ness of the different treatments.
Material and methods A self-administered survey was con-
ducted on a sample of 80 psychiatrists proceeding on a wide
array of mental health care services. Participants provided socio-
demographic data and information about clinical details, together
with their opinions regarding the, epidemiological aspects, clini-
cal management, diagnosis and therapy. Descriptive statistics were
subsequently calculated with SPSS.
Results Most of our sample’s of Psychiatrists estimated that the
DD prevalence was higher than the one previously established.
Ninety-three percent of the sample considered the SGAs as the
first treatment option in DD, being Aripiprazol 20.7%, Risperidone
17.4% and Paliperidone 15% the first line treatment chosen by our
Psychiatrists.
Conclusions and proposals There is an increasing gap between the
old standard DD treatment and the clinical practice of Andalusian
Psychiatrists, for this reason we emphasize the need of implement-
ing clinical trials and effectiveness clinical studies.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1126
Psychiatrists’ opinion on treatment
adherence in Delusional Disorder
B. Girela Serrano ∗, L. Aguado Bailón , P. Calvo ,
J.E. Mu˜noz Negro , J. Cervilla Ballesteros
1 Hospital Santa Ana Motril, Psiquiatría, Motril, Granada, Spain
2 Hospital Universitario San Cecilio, Psiquiatría, Granada, Spain
∗ Corresponding author.
Introduction Delusional Disorder (DD) F22 is a disease with low
prevalence, probably underdiagnosed by clinical specialists due to
the high level of functionality, low awareness of disease, low dete-
rioration of patients and poor adherence to prescribed treatment.
Adherence to treatment is considered to be one of the major diffi-
culties that stand in the way of the treatment of DD. The present
paper assessed psychiatrists ´opinion of the adherence to treatment
of patients with DD.
Material and methods A self-administered survey was conducted
on a sample of psychiatrists proceeding on a wide array of mental
health care services. Participants provided their opinions regarding
adherence to treatment. Descriptive statistics were subsequently
calculated with SPSS.
Results In the opinion of our participants none of the patients
have an active compliance of the treatment, 36% consider that the
participation is partial or passive. It is also estimated that 57.5%
reject the treatment but not totally and 6.5% believe that rejection
is absolute.
Conclusions Literature informs of the association of poor adher-
ence to treatment and little or no improvement of patients,
suggesting the need to address the lack of compliance and adher-
ence to treatment as a crucial aspect to improve the prognosis of
DD. To address this problem Long Acting Injections (LAIs) of Atypi-
cal Antipsychotics are postulated to be a plausible solution as a good
treatment strategy. In order to improve the clinical practice in DD
and obtain information for further effectiveness we emphasize the
need of implementing clinical studies.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.